Janus Pharmaceuticals, Inc Company Profile

01:55 EDT 18th March 2018 | BioPortfolio

Janus was founded in 2004 by Catalyst Pharma Group Inc. (CPG), a clinical development services company in the United States and aRigen, Inc., a private equity backed bio-medical venture company in Japan. aRigen and CPG identified the value in creating topical formulations of novel anti-infective products discovered in Japan and developing and commercializing these products in the United States.


1111 S. Arroyo Parkway, Suite 200
United States of America


Phone: (626) 568-0762
Fax: (626) 568-8667

News Articles [526 Associated News Articles listed on BioPortfolio]

Mylan (MYL) Stake Boosted by Janus Henderson Group PLC

Janus Henderson Group PLC lifted its holdings in Mylan by 56.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 114,620 shares of the company's ...

Mylan N.V. (MYL) Position Trimmed by Janus Henderson Group PLC

Janus Henderson Group PLC lowered its position in Mylan N.V. by 36.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 73,231 shares of the company's stock ...

Global and Chinese Cancer Janus Kinase Inhibitor Industry, 2017 Market Research Report [Report Updated: 20122017] Prices from USD $3000

The 'Global and Chinese Cancer Janus Kinase Inhibitor Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Cancer Janus Kinase Inhibitor in...

Autoimmune Disorder Treatment Placed On Fast Track By FDA

NewsCTP-543 is a novel oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in...

Janus Kinase 3 JAK3 Inhibitor Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

Janus Kinase 3 JAK3 Inhibitor Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across Janus Kin...

Bay Area Bigfoot Biomedical Bags $37M Series B Financing

The round was co-led by funds managed by new investor Janus Henderson Investors.

FDA Grants Fast Track Designation to Concert’s CTP-543 for the Treatment of Alopecia Areata

LEXINGTON, Mass.–(BUSINESS WIRE)–Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-5...

Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]


Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]


PubMed Articles [201 Associated PubMed Articles listed on BioPortfolio]

Stable Janus superhydrophilic/hydrophobic nickel foam for directional water transport.

Janus superhydrophilic/hydrophobic macroporous nickel foam for directional water transport has been demonstrated via a simple floating strategy. Water can transport from hydrophobic to superhydrophili...

Curvature-mediated assembly of Janus nanoparticles on membrane vesicles.

Besides direct particle-particle interactions, nanoparticles adsorbed to biomembranes experience indirect interactions that are mediated by the membrane curvature arising from particle adsorption. In ...

Electrospun Hydrophilic Janus Nanocomposites for the Rapid Onset of Therapeutic Action of Helicid.

The oral delivery of active ingredients for the fast onset of therapeutic effects is a well-known method in patients. In this study, a new kind of hydrophilic Janus structural nanocomposites was desig...

Janus Iron Oxides @ Semiconducting Polymer Nanoparticle Tracer for Cell Tracking by Magnetic Particle Imaging.

Iron oxides nanoparticles tailored for magnetic particle imaging (MPI) have been synthesized, and their MPI signal intensity is 3 times of commercial MPI contrast (Ferucarbotran, also called Vivotrax)...

Chronic active Epstein-Barr virus infection as the initial symptom in a Janus kinase 3 deficiency child: Case report and literature review.

With the progress of sequencing technology, an increasing number of atypical primary immunodeficiency (PID) patients have been discovered, including Janus kinase 3 (JAK3) gene deficiency.

Clinical Trials [222 Associated Clinical Trials listed on BioPortfolio]

A Single Center Prospective Randomized Controlled Clinical Study of JANUS Stent in Patients With Coronary Artery Disease

Janus stent is the only marketed drug-eluting stent (DES) without polymer coating as yet in China. The goal of this study is to evaluate the efficacy of JANUS (Tacrolimus eluted stent) i...

This is a Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor in Patients With Multiple Myeloma

The purpose of this study is to determine clinical efficacy and safety of INCB018424, a small molecule Janus kinase (JAK) inhibitor, in patients with refractory or relapsed multiple myelom...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1305 Associated Companies listed on BioPortfolio]

Janus Pharmaceuticals, Inc

Janus was founded in 2004 by Catalyst Pharma Group Inc. (CPG), a clinical development services company in the United States and aRigen, Inc., a private equity backed bio-medical venture company in Jap...


We offer a broad range of investment options, but our expertise is in growth and risk-managed funds. Some of us are driven by a never-ending search for an information advantage. Others by an unwaverin...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

More Information about "Janus Pharmaceuticals, Inc" on BioPortfolio

We have published hundreds of Janus Pharmaceuticals, Inc news stories on BioPortfolio along with dozens of Janus Pharmaceuticals, Inc Clinical Trials and PubMed Articles about Janus Pharmaceuticals, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Janus Pharmaceuticals, Inc Companies in our database. You can also find out about relevant Janus Pharmaceuticals, Inc Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record